Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Rowe

Showing results (411-420 of 504) with videos related to

Pageof 51
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 26, 2026
Prognostic Value of Early Follow-Up PSMA PET/CT After 2 Cycles of [<sup>177</sup>Lu]Lu-PSMA RPT in Patients with mCRPC: Comparison with PSA DynamicsLiam Widjaja, Johannes Hornfeck, Sophie C Siegmund, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 30, 2020
High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CTRudolf A Werner, Thorsten Derlin, Steven P Rowe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical ProstatectomyLiang Dong, Yun Su, Yinjie Zhu, et al.
Cancers|January 21, 2022
Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CTPatrick W Mihatsch, Matthias Beissert, Martin G Pomper, et al.
Science Advances|July 9, 2019
Imaging CAR T cell therapy with PSMA-targeted positron emission tomographyIl Minn, David J Huss, Hye-Hyun Ahn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2023
SUVPhilipp E Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, et al.
Molecular Oncology|August 17, 2018
From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world settingSteven P Rowe, Brandon Luber, Monique Makell, et al.
Advances in Radiation Oncology|April 14, 2020
Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate CancerWilliam T Hrinivich, Ryan Phillips, Angela J Da Silva, et al.
The Journal of Urology|October 18, 2024
Clinical Factors Associated With Suspicious <sup>18</sup>F-DCFPyL Prostate-Specific Membrane Antigen Positron Emission Tomography Activity in Patients Initially Managed With Radical Prostatectomy Including Prostate-Specific Antigen < 0.5 ng/mLEric V Li, Richard Bennett, Austin Ho, et al.
Molecular Imaging and Biology|July 30, 2024
Imaging of Chromophobe Renal Cell Carcinoma with <sup>99m</sup>Tc-Sestamibi SPECT/CT: Considerations Regarding Risk Stratification and Histologic ReclassificationSteven P Rowe, Salikh Murtazaliev, Jorge D Oldan, et al.
Pageof 51

Showing results (411-420 of 504) with videos related to

Sort By:
Pageof 51
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 26, 2026
Prognostic Value of Early Follow-Up PSMA PET/CT After 2 Cycles of [<sup>177</sup>Lu]Lu-PSMA RPT in Patients with mCRPC: Comparison with PSA DynamicsLiam Widjaja, Johannes Hornfeck, Sophie C Siegmund, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 30, 2020
High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CTRudolf A Werner, Thorsten Derlin, Steven P Rowe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical ProstatectomyLiang Dong, Yun Su, Yinjie Zhu, et al.
Cancers|January 21, 2022
Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CTPatrick W Mihatsch, Matthias Beissert, Martin G Pomper, et al.
Science Advances|July 9, 2019
Imaging CAR T cell therapy with PSMA-targeted positron emission tomographyIl Minn, David J Huss, Hye-Hyun Ahn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2023
SUVPhilipp E Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, et al.
Molecular Oncology|August 17, 2018
From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world settingSteven P Rowe, Brandon Luber, Monique Makell, et al.
Advances in Radiation Oncology|April 14, 2020
Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate CancerWilliam T Hrinivich, Ryan Phillips, Angela J Da Silva, et al.
The Journal of Urology|October 18, 2024
Clinical Factors Associated With Suspicious <sup>18</sup>F-DCFPyL Prostate-Specific Membrane Antigen Positron Emission Tomography Activity in Patients Initially Managed With Radical Prostatectomy Including Prostate-Specific Antigen < 0.5 ng/mLEric V Li, Richard Bennett, Austin Ho, et al.
Molecular Imaging and Biology|July 30, 2024
Imaging of Chromophobe Renal Cell Carcinoma with <sup>99m</sup>Tc-Sestamibi SPECT/CT: Considerations Regarding Risk Stratification and Histologic ReclassificationSteven P Rowe, Salikh Murtazaliev, Jorge D Oldan, et al.
Pageof 51